Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Slideshows|July 8, 2021
6 New Drugs Approved for Primary Care: Q2 2021
Author(s)Sydney Jennings
Advertisement
Another quarter has come and gone, which means Patient Care Online has compiled a list of 6 new FDA-approved drugs for conditions that are often seen in primary care. Scroll through the slides below to find details on the first and only antihistamine nasal spray for allergies available over-the-counter in the US, the first drug approved for chronic weight management since 2014, and 4 more.
Advertisement
Related to this article
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
ACOG's new guideline covers hormone therapy timing, neurokinin receptor antagonists, SSRIs/SNRIs, and nonpharmacologic options for menopause symptoms.
FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
Advertisement
Advertisement
Trending on Patient Care Online
1
Who Should Get a CGM? Expanding the Primary Care Candidate Pool
2
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
3
ACOG Issues Expanded Guideline on Managing Menopause-Related Vasomotor, Sleep, and Mood Symptoms
4
Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease
5